project id: TCGA-PAAD; case submitter id: TCGA-2J-AABO; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.85; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.32; rna integrity number: 8.0; age at index: 43; days to birth: -15869; ethnicity: not reported; gender: male; race: white; vital status: Alive; year of birth: 1970; age at diagnosis: 15869; ajcc pathologic m: M0; ajcc pathologic n: N1; ajcc pathologic stage: Stage IIB; ajcc pathologic t: T3; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 440.0; icd 10 code: C25.0; last known disease status: not reported; morphology: 8500/3; primary diagnosis: Infiltrating duct carcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Head of pancreas; synchronous malignancy: No; tissue or organ of origin: Head of pancreas; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: yes; alcohol history: No; cigarettes per day: 0.410958904109589; pack years smoked: 7.5; years smoked: 10.0; is ffpe: false; composition: Not Reported; days to collection: 314; days to sample procurement: 0; initial weight: 160.0; portion submitter id: TCGA-2J-AABO-01A-21; percent lymphocyte infiltration: 12.0; percent monocyte infiltration: 2.0; percent necrosis: 0.0; percent neutrophil infiltration: 10.0; percent normal cells: 5.0; percent stromal cells: 60.0; percent tumor cells: 35.0; percent tumor nuclei: 35.0;